Menu Search
Equities

Royal Prima Tbk PT

PRIM:JKT

Royal Prima Tbk PT

Actions
Health CareHealth Care Providers
  • Price (IDR)58.00
  • Today's Change-4.00 / -6.45%
  • Shares traded17.84m
  • 1 Year change-38.30%
  • Beta0.2309
Data delayed at least 10 minutes, as of Jul 05 2024 10:11 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Royal Prima Tbk is an Indonesia-based healthcare services company. The Company provides hospital services, clinics, polyclinics and related business activities. The Company operates Royal Prima Medan and Royal Prima Jamb hospital. The Company provides an orthopedic specialist, eye specialist, neurologist, internal medicine specialist, obstetrics and gynecology specialist, heart specialist, lung specialist, child specialist, ENT-KL specialist and urologist. It also provides a general surgeon, surgical oncology specialist, plastic surgery specialist, pediatric surgeon, neurosurgeon, digestive surgery specialist, skin and genital specialist, psychiatric specialist, dental polyclinic and others. Its services include NICU, nursery, physiotherapy, maternity room and others.

  • Revenue in IDR (TTM)275.63bn
  • Net income in IDR382.66m
  • Incorporated--
  • Employees784.00
  • Location
    Royal Prima Tbk PTJl Ayahanda No 68AJAKARTA BARAT 11480IndonesiaIDN
  • Phone+62 2 188813182
  • Fax+62 2 180013181
  • Websitehttps://www.royalprima.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.